<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190305042927N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-26</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>the effect of aloe vera gel on prevention of SG</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effect of aloe vera gel on prevention of SG in nulliparous woman</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/38083</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Using random allocation software1.0, A simple random list of 3 groups with codes A, B and C for 90 participants was prepared and presented by a statistical consultant. The codes were placed in envelopes in the order of the list provided in the form of small cards by the research colleague, the lids of the envelopes were pasted and the envelopes were numbered in the order in the list obtained from the random assignment software. Envelopes were given to the researcher who was doing the sampling. Eligible individuals were opened to enter the study envelope in order and the group was identified, Blinding description: Researchers, participants, and data analyzers were not aware of the gel type.
After preparing by the Pharmacognosy Center, the gels were named in the same package with codes A and B. At the end of the data analysis, the results were announced to the Pharmacognosy Center and the type of gel of each code was announced by that center.At the same time, the research colleague, who evaluated the outcome by observing and completing the observation checklist, did not know what the study groups (A, B, C) were receiving.</study_design>
      <phase>3</phase>
      <hc_freetext>Striea gravidarum.</hc_freetext>
      <i_freetext>Intervention 1: "Intervention group:" Receive aloe vera gel 75% from the 20th week of pregnancy to 28 pregnancies once a day in the amount of 5 grams or the equivalent of approximately 3 fingertips with 2 minutes of massage on the entire abdomen. Intervention 2: "Control group 1:" Receive placebo gel (Base gel without active ingredient) from the 20th week of pregnancy to 28 pregnancies once a day in the amount of 5 grams or approximately the equivalent of 3 fingertips with 2 minutes of massage on the entire abdomen. Intervention 3: "Control group 2:" During the study (28-20 weeks of pregnancy) did not use any substance in the abdomen.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Official request through corresponding researcher

When:
One year after article published.

To whom:
Universities and Research Centers

Conditions:
Confidentiality and obtaining permission from the main researcher

Where to obtain:
Corresponding authors' email

How to obtain:
After emailing and stating the reason for asking for the dat

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Bagherian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vali-Asr Avenue, Vali-Asr and Neiaiesh Highway Intersection, Opposite Rajae Hospital, Nursing and Midwifery School</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996835119</zip>
        <telephone>+98 21 8820 2512</telephone>
        <email>bagherian.midwife94@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nourossadat Kariman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vali-Asr Avenue, Vali-Asr and Neiaiesh Highway Intersection, Opposite Rajaee Heart Hospital,School of Nursing and Midwifery</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996835119</zip>
        <telephone>+98 21 8820 2512</telephone>
        <email>n_kariman@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Nulliparus
Single pregnancy
Age:20-35 year</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of previous striae in the abdomen
History of skin diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"Intervention group:" Receive aloe vera gel 75% from the 20th week of pregnancy to 28 pregnancies once a day in the amount of 5 grams or the equivalent of approximately 3 fingertips with 2 minutes of massage on the entire abdomen.</i_keyword>
      <i_keyword>"Control group 1:" Receive placebo gel (Base gel without active ingredient) from the 20th week of pregnancy to 28 pregnancies once a day in the amount of 5 grams or approximately the equivalent of 3 fingertips with 2 minutes of massage on the entire abdomen.</i_keyword>
      <i_keyword>"Control group 2:" During the study (28-20 weeks of pregnancy) did not use any substance in the abdomen</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Stria score in the Davy checklist. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Davy method: The number of striae in each quarter of the abdomen is scored: "Score zero, no striae", "score one, number 2 striae", "score two, number 3-3 striae" and a total score of 0-0. . The final evaluation of striae severity is done in three groups: "zero without striae", "2-1 moderate striae" and "3-8 severe striae".</prim_outcome>
      <prim_outcome>Severity ofstriae pruritus. Timepoint: 8 weeks after the intervention. Method of measurement: It was evaluated by Kamini method with a score of 4-0. Without itching "score 0", mild itching (1-2 times a day) "score 1", moderate itching without disruption of daily work (3-4 times a day) "score 2", severe itching (6- 5 times a day) annoying daily work "score 3" and severe itching throughout the day and disturbing work and sleep "score 4".</prim_outcome>
      <prim_outcome>Severity of striae erythema. Timepoint: 8 weeks after the intervention. Method of measurement: By the way of Atval Assessed with a score of 3-0: no erythema "score 0", moderate erythema (bright red or pink) "score 1", symptomatic erythema (red) "score 2", severe erythema (purple) "score 3" Was considered.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-03</approval_date>
        <contact_name>Ethics committee of Shahid beheshti University of Medical Sciences</contact_name>
        <contact_address>Yemen St. - Shahid Abbas Arabi St. (Parvaneh) - Next to Taleghani Hospital - Shahid Beheshti University of Medical Sciences and Health Services - Headquarters Building 2- Floor 5- Deputy of Research and Technology Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
